The anticancer drug daratumumab appears to offer significant benefits – including a promising safety profile – when used as part of a three-drug regimen to treat patients with immunoglobulin light-chain amyloidosis, a protein disorder that most commonly affects the heart and kidneys.
Research Shows Daratumumab’s Effectiveness in AL Amyloidosis
Recent Cleveland Clinic Cancer Center research shows the monoclonal antibody daratumumab is a safe, effective and fast-acting treatment for amyloid light-chain amyloidosis, producing a hematologic response in more than 80% of relapsed/refractory patients in a small cohort study.